Infectious disease

Using a new genome analysis technology, A*STAR scientists discover never-before-seen immune responses in tuberculosis infections.

During the 2018 outbreak in Southeastern Tanzania, there were four dengue virus serotypes and the chikungunya virus in circulation, say A*STAR researchers.

A new, cost-effective barrier enclosure protects healthcare workers by effectively containing airborne viral particles from COVID-19 patients.

This two-step outbreak detection framework could give early warnings of dengue outbreaks, improving Singapore’s ability to control the disease.

Horizontal Technology Programme Offices will bring A*STAR’s deep capabilities to bear on real-world issues facing Singapore and the wider world, says Deputy Chief Executive (Research), Andy Hor.

Plant-based ionizers are surprisingly effective at removing aerosols and could play an important role in preventing COVID-19 transmission.

New clues into how the immune system remembers a dengue infection may lead to a better vaccine.

Antiviral strategies against COVID-19 broadly fall into two groups: those that target the virus and those that target the host factors that are essential for virus replication.

Tipped off by artificial intelligence, a research team is testing whether a rheumatoid arthritis drug could be repurposed as a COVID-19 treatment.

Researchers at A*STAR have uncovered a new role for a subset of immune cells in HIV infection and transmission.

Targeted mutagenesis is being used to create live-attenuated vaccines against the chikungunya virus.

A*STAR researchers have identified four peptide sequences that distinguish the Zika virus from other flaviviruses, with implications for diagnostics and vaccine development.